SuperworthEnovis CORP ENOV
- Market cap
- $1.2B
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 0.5×
- EV/EBIT
- 191×
- Revenue, 12 months
- $2.3B
- +5% on a year ago
- Net margin
- −48.0%
- Free cash flow yield
- 5.2%
Enovis CORP trades at 0.5× sales. Its trailing earnings are negative, so it has no PE. Revenue was $2.3B over the last twelve months, up 5% on a year earlier with a −48% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $417.5M+9% | $455M+11% | $516.3M+27% | $525.2M+23% | $505.2M+21% | $561M+23% | $558.8M+8% | $564.5M+8% | $548.9M+9% | $575.8M+3% | $589.2M+5% | $582.8M+3% | |
| Cost of revenue | $174.6M+4% | $190.6M+8% | $218.4M+28% | $236.3M+31% | $218.8M+25% | $253.5M+33% | $226.6M+4% | $229.8M−3% | $220M+1% | $226.3M−11% | $223.7M−1% | $223.5M−3% |
| Gross profit | $243M+13% | $264.4M+14% | $297.9M+27% | $288.9M+16% | $286.5M+18% | $307.5M+16% | $332.2M+12% | $334.7M+16% | $328.9M+15% | $349.4M+14% | $365.5M+10% | $359.2M+7% |
| R&D | $19.9M+28% | $18.3M+24% | $23.4M+29% | $23.5M+24% | $20.5M+3% | $24M+31% | $28.5M+22% | $30.7M+31% | $29.7M+45% | $31.4M+31% | $31.5M+11% | $31.7M+3% |
| SG&A | $204.2M+12% | $211M+1% | $255.7M+23% | $264.1M+27% | $249.9M+22% | $257.7M+22% | $269M+5% | $267.1M+1% | $263.6M+6% | $270.4M+5% | $282.8M+5% | $263.7M−1% |
| −$20.5M+14% | −$5.8M−80% | −$35M+40% | −$44.2M+205% | −$31.7M+55% | −$664.7M+11451% | −$46.8M+34% | −$16.8M−62% | −$558.5M+1660% | −$502.2M−25% | $6.5M | $17.4M | |
| Interest expense | $5.8M−9% | $4.3M−30% | $20M+254% | $17M+316% | $11.1M+92% | $9.1M+113% | $9.2M−54% | $9.3M−45% | $8.8M−20% | $7.5M−17% | $9.2M−0% | $8M−14% |
| Pre-tax income | −$25.5M−67% | $7.7M | −$79.2M+165% | −$27.4M+42% | −$42.6M+67% | −$673.7M | −$57.3M−28% | −$25.7M−6% | −$566.9M+1231% | −$509.5M−24% | $634K | $7.5M |
| −$6.1M−51% | $4.6M−91% | −$7.4M+4% | −$8.9M+89% | −$9.1M+50% | $29.9M+552% | −$1.8M−76% | $10.8M | $4M | $9.3M−69% | $9M | $8.5M−21% | |
| Net income | −$2.9M−96% | $3M | −$72M+208% | −$18.6M+87% | −$31.5M+995% | −$703.3M | −$56M−22% | −$36.7M+97% | −$571.1M+1712% | −$520.6M−26% | −$8.8M−84% | −$1.2M−97% |
| −$0.05−96% | $0.05 | −$1.32+207% | −$0.34+89% | −$0.58+1060% | −$12.59 | −$0.98−26% | −$0.64+88% | −$9.99+1622% | −$9.10−28% | −$0.15−85% | −$0.02−97% | |
| 54.5M+1% | 54.6M+1% | 54.7M+1% | 54.9M+1% | 55.7M+2% | 55.9M+2% | 56.8M+4% | 57.1M+4% | 57.2M+3% | 57.2M+2% | 57.3M+1% | 57.6M+1% |
Revenue: Q1 FY10 and Q1 FY11: 6 months less the 3 months printed beside them.
Cost of revenue: Q1 FY10 and Q1 FY11: 6 months less the 3 months printed beside them.
Gross profit: Q1 FY10 and Q1 FY11: 6 months less the 3 months printed beside them.
R&D: Q1 FY10 and Q1 FY11: 6 months less the 3 months printed beside them.
SG&A: Q1 FY10: 6 months less the 3 months printed beside them.
Operating income: Q1 FY10 and Q1 FY11: 6 months less the 3 months printed beside them.
Interest expense: Q1 FY10 and Q1 FY11: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY10 and Q1 FY11: 6 months less the 3 months printed beside them.
Income tax: Q1 FY10 and Q1 FY11: 6 months less the 3 months printed beside them.
Net income: Q1 FY10 and Q1 FY11: 6 months less the 3 months printed beside them.
EPS, diluted: 11 periods, Q4 FY12 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY11: share-days: the 6-month average less the second quarter's. 8 periods, Q4 FY12 to Q4 FY23: share-days: the 12-month average less the 9-month, weighted by days. 6 periods, Q4 FY17 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Instruments & Supplies nearest Enovis CORP's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| ENOVEnovis CORP | $1.2B | n/m | 23.7× | 0.5× | +5% | −48.0% | |
| BVSBioventus | $1.3B | 19.4× | 27.2× | 2.2× | +3% | 9.4% | |
| CDRECadre | $1.3B | 37.0× | 35.8× | 1.9× | +20% | 5.3% | |
| STAAStaar Surgical | $1.1B | 323× | 143× | 3.3× | +51% | 1.1% | |
| IRMDIradimed | $1.1B | 47.9× | 41.4× | 12.7× | +11% | 26.7% | |
| EYENational Vision | $1.5B | 30.6× | 53.3× | 0.7× | +8% | 2.5% | |
| LMATLemaitre Vascular | $1.9B | 29.6× | 42.0× | 7.4× | +12% | 25.0% | |
| INSPInspire Medical Systems | $2.1B | 15.4× | 58.0× | 2.3× | +4% | 15.0% | |
| MOVMovado | $701.9M | 17.5× | 13.3× | 1.0× | +5% | 6.0% | |
| UFPTUFP Technologies | $2.3B | 31.9× | 25.6× | 3.6× | +7% | 11.4% | |
| MDXGMimedx | $569.9M | 97.8× | 21.1× | 1.6× | −2% | 1.8% | |
| Peer median | $1.3B | 31.2× | 38.6× | 2.2× | +8% | 7.7% |
More on Enovis CORP
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .